Kornimate/medical-research-clean huggingface dataset:
angiography-derived quantitative functional assessment versus pressure-derived ffr and imr: the fair study

Conditions: Coronary Artery Disease; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Coronary Stenosis; Vascular Diseases; Ischemia

Summary: coronary angiography-derived ffr assessment (angioqfa) is a novel technique for physiological lesion assessment based on 3-dimensional (3d) quantitative coronary angiography (qca) and virtual hyperemic flow derived from contrast frame count without drug-induced hyperemia. the goal of this prospective, multicenter trial is to compare the diagnostic performance of angioqfa with invasive ffr as the reference standard. the secondary purpose is to compare the diagnostic accuracies of the computational fluid dynamics (cfd)-based index of microcirculatory resistance (imr) using wire-based imr as the reference standard.


Eligibility criteria:
inclusion criteria * general inclusion criteria: 1. age ≥18 years. 2. coronary angiography is required for patients with suspected or confirmed coronary artery disease. 3. the subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. * angiographic inclusion criteria: 1. diameter stenosis of 30%-90% by visual estimate 2. reference vessel size ≥2 mm in stenotic segment by visual estimate exclusion criteria: patients meeting any of the following criteria will be excluded: * general exclusion criteria: 1. subject has undergone cabg of the target vessel. 2. evidence of an acute myocardial infarction within one week prior to the intended procedure. 3. severe heart failure (nyha≥iii) 4. patients with other serious conditions not eligible for clinical trials, such as severe arrhythmia or tachycardia, sinus syndrome, asthma, severe chronic obstructive pulmonary disease. 5. serum creatinine level of \>150µmol / l. 6. subject has known allergy to iodinated contrast agents, adenosine, or atp. 7. pregnant or breastfeeding. 8. repeated enrollment. 9. any other factors that the researchers consider not suitable for diagnostic intervention or ffr and imr detection, such as the target vessel has collateral circulation, coronary spasm, the target vessel plaque rupture resulting in myocardial infarction, or other reasons deemed unsuitable for inclusion. * angiographic exclusion criteria: 1. myocardial bridge or coronary artery fistula on the study lesions. 2. the target lesion ≥50% diameter stenosis in the left main coronary artery or ostial lesions less than 3 mm to the rca. 3. low-quality angiography with poor contrast agent filling or inability to detect vascular boundaries due to various reasons, vascular overlap or severe distortion of the target vessel to fully expose the lesion location is not expected to be calculated.
somatostatin analogue treatment of acromegaly: molecular aspects

Conditions: Acromegaly; Metabolic Diseases

Summary: the treatment with sa still leaves some questions unanswered. firstly, sa treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. secondly, the traditional evaluation of disease activity by measuring circulating levels of gh and total igf-i is not reliable enough hypotheses: treatment of acromegaly with sa versus surgery alone is associated with: * glucose intolerance despite normalized insulin sensitivity * modified peripheral gh activity in peripheral target organs assessed on molecular endpoints

acromegaly is a rare disease usually caused by a benign growth hormone (gh) producing pituitary adenoma. in case of inadequate disease control, the condition is associated with significant morbidity and approximately a doubling of mortality compared to the background population. medical treatment with somatostatin analogues (sa) has been employed for about 20 years and is a well-established treatment in cases where surgery is impossible or inadequate. the treatment with sa still leaves some questions unanswered. firstly, sa treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. secondly, the traditional evaluation of disease activity by measuring circulating levels of gh and total igf-i is not reliable enough

Eligibility criteria:
inclusion criteria: * \> 18 years * treated acromegaly * considered suitable exclusion criteria: * pregnancy

Keywords: acromegaly somatostatin treatment metabolic effect
a study of ly3372993 in healthy participants and participants with alzheimer's disease (ad)

Conditions: Alzheimer Disease

Summary: the main purpose of this study is to evaluate the safety and tolerability of ly3372993 in healthy participants and participants with ad. the study will also investigate how much ly3372993 gets into the bloodstream and test the effects of ly3372993 in participants with ad. the study has two parts: * part a - healthy participants will receive ly3372993 or placebo. part a will last up to 17 weeks; * part b - participants with ad will receive ly3372993 or placebo. part b will last about 317 days.

in april, 2019, eli lilly and company made a business decision to terminate part b. no participants were enrolled.

Eligibility criteria:
inclusion criteria : part a: * overtly healthy males or females as determined by medical history and physical examination * are between 18 to 45 years old, inclusive * male participants agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product * female participants not of child-bearing potential * have a body mass index of 18.0 to 32 kilograms per square meter (kg/m²) inclusive part b: * present with mild cognitive impairment (mci) due to alzheimer's disease (ad) or mild-to-moderate ad * positive florbetapir scan * men or nonfertile women, at least 55 years of age. nonfertile is defined as hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year * have up to 2 study partners who can provide health information related to the study about the participant. study partner(s) will provide a separate written informed consent to participate exclusion criteria: * have significant abnormalities in brain magnetic resonance imaging (mri); or have contraindications for mri * have significant allergic reactions to ly3372993, or related compounds, or have significant allergies to humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone * have clinically significant neurological or psychological illness, or other illnesses that could affect the study results part a: * have family history of early onset alzheimer's disease (ad) * have impaired cognitive function part b: * history of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, or stroke or epilepsy * previously dosed in any other study investigating active immunization against amyloid beta (aβ) * previously dosed in any other study investigating passive immunization against aβ within the last 6 months * have current serious or unstable illnesses
reflexology's effect on polycystic ovary syndrome: a pilot study

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is very common, affecting approximately 5% of women of reproductive age, and impacts not only on quality of life, but also has long-term health consequences for many sufferers, such as increased risks of developing type ii diabetes, cardiovascular disease and cancer of the womb. the symptoms that may occur such as irregular periods; lots of body hair; thinning hair on scalp, obesity and infertility, can also lead to poor self-esteem. whilst treatments can help fertility, other treatments to correct the other symptoms are less successful. alternative methods to regulate periods would be helpful, especially ones which avoid the long-term use of steroids in patients who may already be overweight. reflexology is poorly represented in scientific papers, with nothing published regarding reflexology and its effect upon pcos. however patients who use reflexology report more regular periods, thicker hair on scalp and greater wellbeing. therefore we aim to investigate the effect of reflexology on: 1. the menstruation cycle (normal being every 21-35 days). 2. imbalances in hormone, insulin and blood sugar levels associated with pcos. 3. other problems associated with pcos such as thinning hair on scalp, excessive body hair, and obesity. 4. quality of life. government and nhs agendas agree that if there's evidence of an effective complimentary therapy the nhs should provide it. therefore the results may have an influence on the care pathways of patients with pcos towards a more holistic, patient centred and empowered approach. it is also non invasive and liable to result in higher patient satisfaction regarding their treatment. this research may also inform policy makers so that complementary medicine provision is provided on a wider basis within the nhs, which at the moment is dictated by the individual trust's budget allocation. however this research could save money overall as in america, the yearly cost of treating pcos is $4.36 billion.


Eligibility criteria:
inclusion criteria: * women with pcos exclusion criteria: * use of complimentary therapies within 6/12 prior to recruitment * bmi \>35 * taken combined oral contraceptives, metformin, or cyclical progestogens within 3/12 prior to recruitment

Keywords: polycystic ovary syndrome reflexology complementary and alternative medicine endocrinopathy oligo amenorrhoea
antibiotic use in facial fracture post injury

Conditions: Trauma Injury

Summary: facial fractures make up a significant proportion of injuries in trauma patients (1, 2). approximately 3 million individuals suffer craniofacial trauma in the united states on a yearly basis, and approximately 50% of all wounds presenting to emergency rooms involve the head and neck (1, 2). treatment of these fractures often results in standard surgical interventions. while up to the early 1980's perioperative antibiotic prophylaxis in maxillofacial surgery was controversial, its efficacy is well accepted today (3). previous research work showed that the administration of antibiotics one hour preoperatively and eight hours after the intervention reduces the incidence of infectious complications in facial fractures from 42.2% to 8.9% (4). however there is still no consensus about the duration of the postoperative administration. in literature postoperative prophylaxis in facial fractures varies from single-shot up to duration of 7 and even ten days postoperatively. the use of antibiotics can be associated with allergic or toxic reactions, adverse effects, drug interactions and increasing bacterial resistance (5). in addition some authors assume that a prolonged administration of antibiotics might increase the risk of infectious complications via superinfection. on the other hand a short term or single shot administration might not be enough to prevent the onset of a postoperative infection. up to date there is no standard to support the duration of antibiotic administration after surgical repair of a facial fracture. in this proposal, investigators are aiming to investigate if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures.

this proposed research is a retrospective chart review to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures. records of trauma patients who were admitted to methodist health system (mhs) between january1st 2010 and december 31st 2015 will be retrieved to review the clinical charts according to our inclusion and exclusion criteria. patients will be segregated in to two groups according to the duration of antibiotic use, group 1 (less than 3days) and group 2 (5 days). basic demographics and clinical outcomes parameters as noted above will be attained from the patient's medical records.

Eligibility criteria:
inclusion criteria: * male and female patient's ≥ 18 years of age. * blunt and penetration injury. exclusion criteria: * pregnant and breast feeding women.
nab-paclitaxel combined with oxaliplatin and s-1 for perioperative treatment of advanced gastric cancer

Conditions: Gastric Cancer

Summary: this is a prospective, single-center, open, historically controlled real-world study. the aims of this study is to evaluate the safety and effectiveness of nab-paclitaxel combined with oxaliplatin and s-1 in the treatment of patients with advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * gastric adenocarcinoma diagnosed by histology. * ambulatory cases, 18-75 years old * ecog performance status ≤ 1 * have not received anti-tumor therapy previously (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy) * patients able to tolerate abdominal surgery above grade 3 * has adequate organ function as defined by the following criteria: * wbc\> 4.0×10\^9/l * anc\> 1.5×10\^9/l * anc ≥ 1.5×10\^9/l * hb ≥ 80 g/l * plt ≥ 100×10\^9/l * tbil ≤ 1.5×uln * alt and ast \<2.5 × uln, for patients with liver metastases, alt and ast \<5 × uln * bun and cr ≤ 1.5 × uln or endogenous creatinine clearance ≥ 50 ml/min * no history of other tumors * be willing and able to comply with the plan during the research period * has given written informed consent * life expectancy ≥ 6 months exclusion criteria: * those with a history of other malignancies in the last 5 years, except for cured non-melanoma skin cancer and cervical carcinoma in situ * her-2+ and willing to receive trastuzumab * pregnancy or breast-feeding women; men and women who are sexually active (possible to have children) and unwilling to use contraception during the study period * severe, uncontrolled medical diseases and infections; chronic bowel disease or short bowel syndrome * major organ failure, such as compensatory cardiopulmonary liver and kidney failure; severe liver and kidney metabolism abnormalities, affecting the normal metabolism of drugs * patients with other surgical contraindications, such as serious diseases that are difficult to control * the researcher believes that patients with a clear gastrointestinal bleeding tendency and/or patients with abnormal blood coagulation function (inr \> 1.5) * active hbv or hcv * peripheral neuropathy ≥ grade 2 according to nct-ctc ae5.0 * patients who are allergic to the drugs in this study, or determined by the investigator as unsuitable to participate in this clinical study
the effect of interval exercise on functional outcomes in veterans with copd and osa

Conditions: COPD; OSA

Summary: the term "overlap syndrome" (os) is used to describe the presence of both chronic obstructive pulmonary disease (copd) and obstructive sleep apnea (osa) in a single patient. due to premature aging, patients with os are prone to developing functional decline up to 20 years earlier than the general population. the international classification of functioning, disability and health (icf) evaluates functional status in chronic pulmonary disease globally in 5 domains. the investigators propose to study validated outcomes in 3 of these domains: 1) participation in life situations; 2) physical activity; and 3) cardiovascular health. the investigators long-term goal is to develop an exercise strategy tailored to veterans with os which will reduce the risk of functional decline through increased pa.

the term "overlap syndrome" (os) is used to describe the presence of both chronic obstructive pulmonary disease (copd) and obstructive sleep apnea (osa) in a single patient. veterans with os who also have excessive daytime sleepiness (eds-os) are at highest risk for functional decline yet have the greatest barriers to exercise training. thus, there is a critical need to identify novel exercise strategies that meet the individual needs and capacities of veterans with eds-os. the investigators propose to test moderate intensity interval training (miit), a novel exercise intervention whose translation into durable lifestyle change may be facilitated by the feasibility of short bouts of increased pa. the investigators proposal addresses key knowledge gaps in rehabilitation research by investigating the clinical phenotype of eds-os to determine the association with functional outcomes and response to a novel exercise intervention with the goal to reduce functional decline.

Eligibility criteria:
inclusion criteria: * diagnosis of copd and osa, i.e., overlap syndrome diagnosis of overlap syndrome (both copd and osa), confirmed in cprs from spirometry or pulmonary function test of fev1/fvc \<70 for copd and a polysomnogram or home-based study for osa. * montreal cognitive assessment (moca) \>20 exclusion criteria: * cad, as defined by anyone of the following: history of cabg, prior positive stress test for ischemia, infarction or angina or medical problem * orthopedic problems as defined by joint pain limiting ambulation * fall risk, defined as more than 2 falls in the prior month * hospitalization in prior month * daytime home oxygen 6. participation in structured exercise, defined by the physical activity scale for the elderly (pase) as more than 1 hour of activity spent in moderate activity and any strenuous activity performed over prior 7 days.

Keywords: copd osa overlap syndrome
health coaching for patients waiting for total hip or knee replacements

Conditions: Arthritis Knee; Arthritis of Hip

Summary: this pilot study aims to evaluate the feasibility of collecting objective data on physical performance to measure the impact of health coaching in addition to a digital resource (active wait) and enable sample size calculation for a larger scale rct.


Eligibility criteria:
inclusion criteria: * patients scheduled on the waitlist for a total joint replacement surgery for hip/knee, ie clinically and radiographically diagnosed, symptomatic knee/hip osteoarthritis deemed suitable for surgical intervention; * have access to the internet and the ability to navigate web-based programs; * able and willing to travel to advanced wellbeing research centre for baseline and follow-up assessments; * able to comprehend the requirements and purpose of the study and give informed consent exclusion criteria: * other musculoskeletal lower limb or back conditions requiring assessment or treatment by a health professional in the last 6 months; * neurological impairment or condition affecting lower limb function; conditions listed as both absolute and relative contraindications for physical activities by the american college of sports medicine (acsm), such as unstable angina, uncontrolled diabetes; * systemic inflammatory disease (e.g. rheumatoid arthritis); * previous total joint replacement surgery (hip or knee)

Keywords: joint replacement surgery digital resource health coaching telehealth self management
polysaccharide antibody response study

Conditions: Specific Polysaccharide Antibody Deficiency

Summary: specific polysaccharide antibody deficiency (spad) is a primary immunodeficiency characterized by a deficient antibody production to capsular polysaccharides with normal total immunoglobulin levels. patients suffer from recurrent ear-nose and throat infections and lung infections. spad can also occur as part of a primary immunodeficiency affecting other components of the immune system. diagnosis of spad is hampered by difficulties with the interpretation of the pneumovax 23 antibody response. the purpose of this study is to assess the diagnostic value of the typhim vi antibody response and allohemagglutinin titers as an alternative to the pneumovax 23 response to detect polysaccharide specific antibody deficiency.

healthy controls (n = 100) and patients with suspected spad (n = 100) will be immunized with both pneumovax 23 and typhim vi (age 18 months - 55 years). analyses of anti-pneumococcal polysaccharide antibodies and anti-vi antibodies are performed before and 3-4 weeks after vaccination. also bloodgroup and anti-a/anti-b are assessed. relevant clinical information (ent infections, lung infections, bronchiectasis, invasive infections) is obtained from the patient file and history and is noted in a case report form. the diagnostic performance of typhim vi response and allohemagglutinins will be analyzed by calculating sensitivity, specificity, predictive values, likelihood ratios and receiver operating characteristic curves for typhim vi and allohemagglutinins using pneumococcal antibody response as the reference standard. the association between low typhim vi response or low allohemagglutinins and clinical signs of polysaccharide antibody deficiency will be studied by multiple logistic regression.

Eligibility criteria:
inclusion criteria: * assessment of polysaccharide antibody response is indicated for the clinical care of the patient (not for healthy volunteers) * informed consent given exclusion criteria: * history of serious adverse reaction to a vaccine * vaccination with typhim vi or pneumovax 23 in 5 years prior to the study * (potential) pregnancy

Keywords: pneumovax 23 typhim vi allohemagglutinins
a study to evaluate the nsaids sparing effect of etanercept in subjects with axial spondyloarthritis

Conditions: Axial Spondyloarthritis

Summary: this study will compare the non steroidal anti-inflammatory drugs (nsaids) sparing effect of etanercept with that of placebo in adult subjects with axial spondyloarthritis.


Eligibility criteria:
inclusion criteria: * male and female subjects aged 18 years and over at the time of consent to the study. * diagnosis of spa, as defined by the asas criteria for axial spa * axial involvement refractory to previous or current intake of nsaids, defined as at least 2 nsaids at maximum tolerated dose determined from past medical history taken for a duration of \> 1 month (for both nsaids combined) before the screening visit. * active axial involvement defined by mini basdai exclusion criteria: * subjects who are investigational site staff members or subjects who are pfizer employees directly involved in the conduct of the trial. * subjects who have received any previous treatment with etanercept or other tnfα inhibitors or biologic agents. * subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients.

Keywords: etanercept axial spondyloarthritis nsaids sparing effect
a study to evaluate a new jaundice stick test

Conditions: Jaundice; Serum Bilirubin

Summary: this is an observational prospective study. the main purpose is to evaluate the stability of the bilistick system in a humid and hot climate compared to the quantitative test for serum bilirubin (sbr) measurement currently used, the br-501 total bilirubin meter, kept in a controlled environment. the secondary aim is to assess the operational feasibility of the bilistick system in a tropical limited-resource setting, when used by locally trained nurses.

study procedure: 1. sbr will be measured in parallel with two tests during three distinct seasons. (cold, hot, rainy). the blood is from an extra capillary sample taken from a single heel prick done for routine sbr) br-501 total bilirubin meter, the quantitative test for sbr currently used, will be kept in a controlled environment while the new bilirubin test (bilistick system) will be exposed to tropical conditions. 2. trained nurses will use the bilistick system observed by a qualified laboratory technician; usability of the bilistick system by the trained nurses will be evaluated via a 5-point likert scale questionnaire and focus groups discussions.

Eligibility criteria:
inclusion criteria: * written or thumb print for informed consent from the parent * infant born ≥ 35 weeks of gestational age * infant who needs a routine sbr measurement * infant in stable clinical condition prior to sbr measurement confirmed by the trained nurses exclusion criteria: the participant will not be enrolled in the study if any of the following applies: * infant who already had 1 sbr measurement done with the bilistick system * last haematocrit measurement \> 65% or no previous haematocrit measurement

Keywords: stick test